|
|
|
| Preparation and Liver-targeted Activity of Poly (γ-glutamic acid)-D-galactose-esterifiable derivative Cisplatin Complex Compound |
|
|
|
Abstract DDP could be easily incorporated into poly (γ-glutamic acid)-D-galactose esterifiable derivative through a covalent bond. The yield of DDP incorporation into the-γ-PGA was 9.4%～10.2%. The DDP was released in the initial 8h in a burst manner, and thereafter in a sustained manner. The results that the conjugation of DDP to poly (γ-glutamic acid)-D-galactose esterifiable derivative not only reduced the toxicity of the DDP but also enhanced antitumor activity and the targeting ability. The vivo experiments conclusively established that the γ-D+-DDP compound was much less toxic to animals than DDP alone. A direct evaluation showed that mice treated with γ-D+-DDP compound at a dose of 7.5 mg/kg displayed significant tumor regression. Furthermore, the implanted solid tumors disappeared completely from 35% of the H22 tumor-bearing mice after γ-D+-DDP compound administration. The aforementioned results of biodistributions of the prepared γ-D+-DDP compound in various organs in normal mice demonstrated that the γ-D+-DDP compound had a specific interaction with liver's parenchymal cells and H22 hepatocellular carcinoma tumor cells via ligand receptor recognition.
In conclusion, the results indicated that the γ-D+-DDP compound prepared can effectively target the site of hepatoma tumor via the recognition and significantly reduce its size. The γ-D+-DDP compound was less toxic than the free DDP, and could effectively reduce xenografted H22 hepatocellular carcinoma cells in KM mice and prolong the survival of KM mice grafted with H22 hepatocellular carcinoma tumor cells. Therefore, the prepared γ-D+-DDP compound may be used as a potential drug delivery system for the targeted delivery to liver cancers or other liver diseases.
|
|
Received: 20 November 2008
Published: 06 May 2009
|
|
|
|
|
| ［1］ Kumar V，Banker G S. Targetedoriented Drug Delivery Systems. In:Banker G S,Rbodes-C-T-eds. Modern-Phannaeeuties.3ed.vol.72.New York: Marcel Dekker,1996,611~680
［2］ Ito Y，Tannka T，Chmachi T. Glutamic acid independent Production of Polyglutamic acid by Bacillus subtilis TMA-4.Biosei Bioteeh Biochem,1996, 60 (8):1239~1242
［3］ Andew M，Daniel B. Advanced anticancer therapy and cytotoxic Medicaments for its implementation:EP,0259904Al,03/16/1998
［4］ 徐风华，蒋雪涛.单克隆抗体表阿霉素免疫偶合物的制备和在体内的活性.药学学报，1996，31(8):632~636
Xu F H, Jiang X T.Acta Pharmaceutica Sinica, 1996, 31(8): 632~636
［5］ Richard G. Immunotoxin conjugate which comprises adsanilic acid, Useful treating matiglant tumors，Particularly Pancreatic cancer:US,4485093,11/27/1984
［6］ Maeda H, Seymour L W, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular the rapeutics in vivo. Biocon Jugate Chem, 1992, 3: 351~362
［7］ Cao X H,Ha Z R,Wang C L, et al. Optimizing fermentation conditions of Poly (γglutamic acid) by Bacillus natto TK2. Food and Fermentation Industry, 2008, 34(I): 24~27
［8］ 杨革，陈坚，曲音波，等.聚γ谷氨酸表征的研究.高分子材料科学与工程，2002, 18 (4): 133~136
Yang G, Chen J, Qu Y B, et al.Polymer Science and Engineering, 2002, 18(4):133~136
［9］ Nakano M M, Magusson R, Myers A, et al.SrfA is an operon required for surfactin production, competence development and efficient sporulation in Bacillus subtilis. J Bacteriol, 1991, 173: 70~78
［10］ Ye H F. Preparation and biological activity of poly (γglutamic acid)cisplatin conjugate.Acta Pharmaceutica Sinica, 2007, 42(6): 611~617
［11］ 邓树海，刘兆平.药物动力学. 北京人民卫生出版社，1998.289
Deng S H,Liu Z P.Pharmacokinetics.Beijing:Beijing People′s Health Press,1998.289
［12］ Rao M V. Solution conformation of poly (LlysylLglutamic acid) and poly (LlysylLglutamine).Protein Res, 1984, 24(1): 48~54
［13］ Dai Y, Liu XJ, Zhen Y S. Antitumor effect of the novel immune conjugate composed of pingyangmyc in and antitype IV collagenase monoclonal antibody. Acta Pharm Sin, 2006, 41: 41~46
［14］ Richard A, Margaritis A. Poly ( glutamic acid) for biomedical applications. CritRev Biotechno, 2001, 21: 219~232
［15］ Li C. Poly (Lglutamic acid)anticancer drug conjugates. Adv Drug Delivery Rev, 2002, 54: 695~713
［16］ Prodhomme E J, Tutt A L, Glennie M J, et al. Multivalent conjugates of poly-gammaD-glutamic acid from Bacillus licheniformis with antibody F(ab’)and glycopeptideligands. Bioconjugate Chem, 2003, 14: 1148 ~1155
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
